GLORIA PHARMA.(SZ:002437) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-04-11 23:47Core Viewpoint - The company has decided to repurchase and cancel a total of 1,653,000 restricted stocks from 8 former incentive recipients, which accounts for 0.07% of the company's total share capital prior to the repurchase [2][9]. Summary by Sections Repurchase Details - The repurchase of the restricted stocks was conducted using the company's own funds, with a total expenditure of RMB 2,094,062.96, calculated at a repurchase price of 1.25 RMB per share plus the interest from the People's Bank of China [2][10][11]. - The repurchase and cancellation procedures have been completed as of the announcement date, with the necessary formalities fulfilled at the Shenzhen branch of China Securities Depository and Clearing Co., Ltd [2][12]. Background of the Repurchase - The incentive recipients, including Li Xiaochuan and Yin Jiao, no longer meet the criteria set forth in the 2024 Restricted Stock Incentive Plan due to their departure from the company [3][9]. - The decision to cancel their incentive qualifications and repurchase the stocks was approved during the board and shareholder meetings held on January 21 and February 6, 2025 [3][9]. Approval Process - The company followed the required approval process for the 2024 Restricted Stock Incentive Plan, which included multiple board meetings and public announcements regarding the incentive recipients [4][5][6]. - Legal opinions were obtained from Beijing Zhide Law Firm regarding the repurchase and cancellation of the restricted stocks [6][9]. Impact on Company - The repurchase of the restricted stocks will not affect the company's stock distribution in a way that violates listing requirements, nor will it have a significant impact on the company's operational performance [12].